X
Xu Wu
Researcher at Harvard University
Publications - 90
Citations - 8006
Xu Wu is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Palmitoylation. The author has an hindex of 42, co-authored 70 publications receiving 6929 citations. Previous affiliations of Xu Wu include Novartis & Genomics Institute of the Novartis Research Foundation.
Papers
More filters
Journal ArticleDOI
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Jun Liu,Shifeng Pan,Mindy H. Hsieh,Nicholas Ng,Fangxian Sun,Tao Wang,Shailaja Kasibhatla,Alwin Schuller,Allen G. Li,Dai Cheng,Jie Li,Celin Tompkins,Anne Marie Pferdekamper,Auzon Steffy,Jane Cheng,Colleen Kowal,Van Phung,Gui-Rong Guo,Yan Wang,Martin P. Graham,Shannon Flynn,J. Chad Brenner,Chun Li,M. Cristina Villarroel,Peter G. Schultz,Xu Wu,Peter McNamara,William R. Sellers,Lilli Petruzzelli,Anthony Boral,H. Martin Seidel,Margaret E. McLaughlin,Jianwei Che,Thomas E. Carey,Gary J. Vanasse,Jennifer L. Harris +35 more
TL;DR: LGK974 is potent and efficacious in multiple tumor models at well-tolerated doses in vivo, including murine and rat mechanistic breast cancer models driven by MMTV–Wnt1 and a human head and neck squamous cell carcinoma model (HN30).
Journal ArticleDOI
A Stem Cell–Based Approach to Cartilage Repair
Kristen Johnson,Shoutian Zhu,Matthew S. Tremblay,Matthew S. Tremblay,Joshua N. Payette,Jianing Wang,Laure C. Bouchez,Shelly Meeusen,Alana Althage,Charles Y. Cho,Xu Wu,Peter G. Schultz +11 more
TL;DR: Using an image-based high-throughput screen, the small molecule kartogenin is identified, which promotes chondrocyte differentiation, showsChondroprotective effects in vitro, and is efficacious in two OA animal models.
Journal ArticleDOI
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Silvia Buonamici,Juliet Williams,Michael Morrissey,Anlai Wang,Ribo Guo,Anthony Vattay,Kathy Hsiao,Jing Yuan,John Green,Beatriz Ospina,Qunyan Yu,Lance Ostrom,Paul Fordjour,Dustin L. Anderson,John Monahan,Joseph Kelleher,Stefan Peukert,Shifeng Pan,Xu Wu,Sauveur Michel Maira,Carlos Garcia-Echeverria,Kimberly J. Briggs,D. Neil Watkins,Yung Mae Yao,Christoph Lengauer,Markus Warmuth,William R. Sellers,Marion Dorsch +27 more
TL;DR: By identifying a drug combination that delays or even combats development of resistance when used as a first-line treatment in clinical trials, these results could ultimately improve the lives of patients with medulloblastoma or other cancers that depend on Smo for their survival.
Journal ArticleDOI
The Renewal and Differentiation of Isl1+ Cardiovascular Progenitors Are Controlled by a Wnt/β-Catenin Pathway
Yibing Qyang,Silvia Martin-Puig,Murali Chiravuri,Shuibing Chen,Huansheng Xu,Lei Bu,Xin Jiang,Lizhu Lin,Anne Granger,Alessandra Moretti,Alessandra Moretti,Leslie Caron,Xu Wu,Jonathan D.W. Clarke,Makoto Mark Taketo,Karl-Ludwig Laugwitz,Karl-Ludwig Laugwitz,Randall T. Moon,Peter J. Gruber,Sylvia M. Evans,Sheng Ding,Kenneth R. Chien +21 more
TL;DR: It is shown that the Wnt/beta-catenin pathway is a major component by which cardiac mesenchymal cells modulate the prespecification, renewal, and differentiation of isl1(+) cardiovascular progenitors.
Journal ArticleDOI
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan,Xu Wu,Jiqing Jiang,Wenqi Gao,Yongqin Wan,Dai Cheng,Dong Han,Jun Liu,Nathan P. Englund,Yan Wang,Stefan Peukert,Karen Miller-Moslin,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Yun Jiang,Jeffrey Tsao,Fangxian Sun,AnneMarie Culazzo Pferdekamper,Stephanie Kay Dodd,Tove Tuntland,Wieslawa Maniara,Joseph Kelleher,Yung-mae Yao,Markus Warmuth,Juliet Williams,Marion Dorsch +27 more
TL;DR: Structural-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl- 3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.